Strategy and tactic of modern Parkinson therapy
Identifieur interne : 001F47 ( Main/Corpus ); précédent : 001F46; suivant : 001F48Strategy and tactic of modern Parkinson therapy
Auteurs : W. Birkmayer ; G. J. D. BirkmayerSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1989-11.
English descriptors
- KwdEn :
Abstract
Abstract– The aim of modern Parkinson therapy is to overcome the dopamine deficit in the brain of parkinsonian patients which is the cause of their motoric disability. This can be achieved in two ways: (a) substitution of the lacking dopamine by ldopa, or (b) stimulation of the endogenous biosynthesis by activating the enzyme tyrosine hydroxylase. The latter approach is possible by the iron compound oxyferriscorbone or by the coenzyme nicotinamide adenine dinucleotide (NADH). In addition to these two major medications the essential therapeutic additives such as the decarboxylase inhibitor benserazide, the monoamineoxidase B inhibitor deprenyl and the dopamine receptor agonist lisuride should be used for the fine adjustment of the individual patient.
Url:
DOI: 10.1111/j.1600-0404.1989.tb01784.x
Links to Exploration step
ISTEX:CA3C614F99A4866CFACB629AAD5FB2A9372FD245Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Strategy and tactic of modern Parkinson therapy</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation><mods:affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Birkmayer, G J D" sort="Birkmayer, G J D" uniqKey="Birkmayer G" first="G. J. D." last="Birkmayer">G. J. D. Birkmayer</name><affiliation><mods:affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CA3C614F99A4866CFACB629AAD5FB2A9372FD245</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1111/j.1600-0404.1989.tb01784.x</idno><idno type="url">https://api.istex.fr/document/CA3C614F99A4866CFACB629AAD5FB2A9372FD245/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Strategy and tactic of modern Parkinson therapy</title><author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name><affiliation><mods:affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</mods:affiliation></affiliation></author><author><name sortKey="Birkmayer, G J D" sort="Birkmayer, G J D" uniqKey="Birkmayer G" first="G. J. D." last="Birkmayer">G. J. D. Birkmayer</name><affiliation><mods:affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11">1989-11</date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="63">63</biblScope><biblScope unit="page" to="66">66</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">CA3C614F99A4866CFACB629AAD5FB2A9372FD245</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01784.x</idno><idno type="ArticleID">ANE63</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>I‐dopa</term><term>NADH</term><term>Parkinson's disease therapy</term><term>deprenyl</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract– The aim of modern Parkinson therapy is to overcome the dopamine deficit in the brain of parkinsonian patients which is the cause of their motoric disability. This can be achieved in two ways: (a) substitution of the lacking dopamine by ldopa, or (b) stimulation of the endogenous biosynthesis by activating the enzyme tyrosine hydroxylase. The latter approach is possible by the iron compound oxyferriscorbone or by the coenzyme nicotinamide adenine dinucleotide (NADH). In addition to these two major medications the essential therapeutic additives such as the decarboxylase inhibitor benserazide, the monoamineoxidase B inhibitor deprenyl and the dopamine receptor agonist lisuride should be used for the fine adjustment of the individual patient.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>W. Birkmayer</name><affiliations><json:string>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</json:string></affiliations></json:item><json:item><name>G.J.D. Birkmayer</name><affiliations><json:string>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>I‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>NADH</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>deprenyl</value></json:item></subject><articleId><json:string>ANE63</json:string></articleId><language><json:string>eng</json:string></language><abstract>Abstract– The aim of modern Parkinson therapy is to overcome the dopamine deficit in the brain of parkinsonian patients which is the cause of their motoric disability. This can be achieved in two ways: (a) substitution of the lacking dopamine by ldopa, or (b) stimulation of the endogenous biosynthesis by activating the enzyme tyrosine hydroxylase. The latter approach is possible by the iron compound oxyferriscorbone or by the coenzyme nicotinamide adenine dinucleotide (NADH). In addition to these two major medications the essential therapeutic additives such as the decarboxylase inhibitor benserazide, the monoamineoxidase B inhibitor deprenyl and the dopamine receptor agonist lisuride should be used for the fine adjustment of the individual patient.</abstract><qualityIndicators><score>3.842</score><pdfVersion>1.4</pdfVersion><pdfPageSize>486 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>759</abstractCharCount><pdfWordCount>1998</pdfWordCount><pdfCharCount>12945</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>112</abstractWordCount></qualityIndicators><title>Strategy and tactic of modern Parkinson therapy</title><genre><json:string>article</json:string></genre><host><volume>80</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>4</total><last>66</last><first>63</first></pages><issn><json:string>0001-6314</json:string></issn><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1111/j.1600-0404.1989.tb01784.x</json:string></doi><id>CA3C614F99A4866CFACB629AAD5FB2A9372FD245</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/CA3C614F99A4866CFACB629AAD5FB2A9372FD245/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/CA3C614F99A4866CFACB629AAD5FB2A9372FD245/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/CA3C614F99A4866CFACB629AAD5FB2A9372FD245/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Strategy and tactic of modern Parkinson therapy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Strategy and tactic of modern Parkinson therapy</title><author><persName><forename type="first">W.</forename><surname>Birkmayer</surname></persName><affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</affiliation></author><author><persName><forename type="first">G.J.D.</forename><surname>Birkmayer</surname></persName><note type="correspondence"><p>Correspondence: Address: Birkmayer‐Institut für Parkinsontherapie Schwarzspanierstraβe 15 A‐1090 Vienna, Austria</p></note><affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11"></date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="63">63</biblScope><biblScope unit="page" to="66">66</biblScope></imprint></monogr><idno type="istex">CA3C614F99A4866CFACB629AAD5FB2A9372FD245</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01784.x</idno><idno type="ArticleID">ANE63</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract– The aim of modern Parkinson therapy is to overcome the dopamine deficit in the brain of parkinsonian patients which is the cause of their motoric disability. This can be achieved in two ways: (a) substitution of the lacking dopamine by ldopa, or (b) stimulation of the endogenous biosynthesis by activating the enzyme tyrosine hydroxylase. The latter approach is possible by the iron compound oxyferriscorbone or by the coenzyme nicotinamide adenine dinucleotide (NADH). In addition to these two major medications the essential therapeutic additives such as the decarboxylase inhibitor benserazide, the monoamineoxidase B inhibitor deprenyl and the dopamine receptor agonist lisuride should be used for the fine adjustment of the individual patient.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease therapy</term></item><item><term>I‐dopa</term></item><item><term>NADH</term></item><item><term>deprenyl</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/CA3C614F99A4866CFACB629AAD5FB2A9372FD245/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="11000"><doi origin="wiley">10.1111/ane.1989.80.issue-s126</doi><numberingGroup><numbering type="journalVolume" number="80">80</numbering><numbering type="supplement">s126</numbering></numberingGroup><coverDate startDate="1989-11">November 1989</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0006300" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1989.tb01784.x</doi><idGroup><id type="unit" value="ANE63"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="63">63</numbering><numbering type="pageLast" number="66">66</numbering></numberingGroup><correspondenceTo>Address: <i>Georg D. Birkmayer, M.D.</i> Birkmayer‐Institut für Parkinsontherapie Schwarzspanierstraβe 15 A‐1090 Vienna, Austria</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE63.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="16"></count><count type="linksCrossRef" number="3"></count></countGroup><titleGroup><title type="main">Strategy and tactic of modern Parkinson therapy</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>W.</givenNames><familyName>Birkmayer</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1" corresponding="yes"><personName><givenNames>G.J.D.</givenNames><familyName>Birkmayer</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="AT"><unparsedAffiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Parkinson's disease therapy</keyword><keyword xml:id="k2">I‐dopa</keyword><keyword xml:id="k3">NADH</keyword><keyword xml:id="k4">deprenyl</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract– </b> The aim of modern Parkinson therapy is to overcome the dopamine deficit in the brain of parkinsonian patients which is the cause of their motoric disability. This can be achieved in two ways: (a) substitution of the lacking dopamine by ldopa, or (b) stimulation of the endogenous biosynthesis by activating the enzyme tyrosine hydroxylase. The latter approach is possible by the iron compound oxyferriscorbone or by the coenzyme nicotinamide adenine dinucleotide (NADH).</p><p>In addition to these two major medications the essential therapeutic additives such as the decarboxylase inhibitor benserazide, the monoamineoxidase B inhibitor deprenyl and the dopamine receptor agonist lisuride should be used for the fine adjustment of the individual patient.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Strategy and tactic of modern Parkinson therapy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Strategy and tactic of modern Parkinson therapy</title></titleInfo><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Birkmayer</namePart><affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.J.D.</namePart><namePart type="family">Birkmayer</namePart><affiliation>Birkmayer Institute for Parkinson‐Therapy Vienna, Austria</affiliation><description>Correspondence: Address: Birkmayer‐Institut für Parkinsontherapie Schwarzspanierstraβe 15 A‐1090 Vienna, Austria</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1989-11</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">16</extent></physicalDescription><abstract lang="en">Abstract– The aim of modern Parkinson therapy is to overcome the dopamine deficit in the brain of parkinsonian patients which is the cause of their motoric disability. This can be achieved in two ways: (a) substitution of the lacking dopamine by ldopa, or (b) stimulation of the endogenous biosynthesis by activating the enzyme tyrosine hydroxylase. The latter approach is possible by the iron compound oxyferriscorbone or by the coenzyme nicotinamide adenine dinucleotide (NADH). In addition to these two major medications the essential therapeutic additives such as the decarboxylase inhibitor benserazide, the monoamineoxidase B inhibitor deprenyl and the dopamine receptor agonist lisuride should be used for the fine adjustment of the individual patient.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease therapy</topic><topic>I‐dopa</topic><topic>NADH</topic><topic>deprenyl</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s126</number></detail><extent unit="pages"><start>63</start><end>66</end><total>4</total></extent></part></relatedItem><identifier type="istex">CA3C614F99A4866CFACB629AAD5FB2A9372FD245</identifier><identifier type="DOI">10.1111/j.1600-0404.1989.tb01784.x</identifier><identifier type="ArticleID">ANE63</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001F47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:CA3C614F99A4866CFACB629AAD5FB2A9372FD245
|texte= Strategy and tactic of modern Parkinson therapy
}}
| This area was generated with Dilib version V0.6.23. |  |